Clinical Trials Logo

Psoriatic Arthritis clinical trials

View clinical trials related to Psoriatic Arthritis.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05715125 Terminated - Psoriatic Arthritis Clinical Trials

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Start date: January 31, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis. Approximately 195 eligible participants will take VTX958 Dose A, VTX958 Dose B, or matching placebo (no active drug) for 16 weeks and then move on to a 36 week Long Term Extension (LTE). The study will include 16 weeks of treatment, 36 weeks of LTE, and a 30-day follow-up period.

NCT ID: NCT05511519 Terminated - Psoriatic Arthritis Clinical Trials

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Start date: July 12, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.

NCT ID: NCT04839315 Terminated - Osteoarthritis Clinical Trials

COVID-19 Vaccination in Rheumatic Disease Patients

Start date: February 15, 2021
Phase: Early Phase 1
Study type: Interventional

The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.

NCT ID: NCT04335747 Terminated - Clinical trials for Rheumatoid Arthritis

COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

Start date: April 23, 2020
Phase:
Study type: Observational

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

NCT ID: NCT04269993 Terminated - Clinical trials for Rheumatoid Arthritis

Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis

Start date: May 18, 2022
Phase: Phase 2
Study type: Interventional

This laboratory study will investigate the impact of cannabis on pain, affect, and inflammation among patients with rheumatoid or psoriatic arthritis (n = 76). Two cannabis formulations varying in potency will be administered via vaporization across two experimental sessions using a counter-balanced, double-blind, crossover design.

NCT ID: NCT04115839 Terminated - Psoriatic Arthritis Clinical Trials

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

PENGUIN 2
Start date: November 13, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis who have an inadequate response or are intolerant to biologic disease-modifying anti-rheumatic drugs (DMARD) therapy.

NCT ID: NCT04115748 Terminated - Psoriatic Arthritis Clinical Trials

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

PENGUIN 1
Start date: December 3, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis who are naive to biologic disease-modifying anti-rheumatic drug (DMARD) therapy. The study consists of two parts, the Main Study and the Long Term Extension (LTE).

NCT ID: NCT03823924 Terminated - Psoriatic Arthritis Clinical Trials

Changes in Body Composition Under Ustekinumab in PsA

STELARA-CC
Start date: March 11, 2019
Phase:
Study type: Observational

There is not much body composition and bone mineral density data available for patients with psoriatic arthritis (rheumatoid arthritis) compared to control subjects. The evaluation of the total fat mass and in particular of its abdominal distribution (visceral adiposity) is important because an excessive adiposity generates adverse effects on the health (hypertension, dyslipidemia, cardiovascular risk and resistance to the insulin). In addition, data on changes in body composition and bone mineral density were not available under a new psA treatment, namely ustekinumab (anti-IL12 / 23 antibody). It is proposed to conduct a pilot study to evaluate body composition, distribution (visceral adiposity) and bone mineral density in patients with psoriatic arthritis (versus control subjects) and their changes after 6 months of treatment with ustekinumab

NCT ID: NCT03454932 Terminated - Clinical trials for Rheumatoid Arthritis

Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases

Start date: May 2015
Phase:
Study type: Observational

Rheumatic diseases regroup a variety of disorders affecting the locomotor system including joints, muscles, connective tissues and soft tissues around the joints and bones. Inflammation and/or autoimmune reactions contribute to the aetiology of many rheumatic diseases. Such autoimmune conditions, commonly referred to as inflammatory rheumatic diseases (IRD), include arthritis of various origins such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) or spondylarthritis (SpA). Patients with autoimmune diseases such as RA or SpA are in higher risk of fractures compared to the general population. Initial pharmacotherapies for IRD remain NSAID treatment for pain relief, and anti-resorptive agents (e.g., TNF-alpha blockers) which aim at reducing bone loss and preventing occurrence of new bone erosions. Yet current treatments may have strong side effects and are not always effective (e.g., 35-40% of the patients treated with TNF-alpha inhibitors will initially or progressively loose response). Therefore there is a need for further treatment modalities in IRD, which would focus on both suppressing inflammation and treating bone disorders. Current research studies indicate that Bone Therapeutics' allogeneic osteoblastic cells exhibit in vitro potent immunosuppressive and anti-inflammatory properties (in addition to osteo-regenerative and immune-privileged properties). The present research study aims at investigating in vitro the properties of these osteoblastic cells in the context of inflammatory rheumatic diseases. In this purpose, in vitro assays will be used to test these immunosuppressive effects on peripheral blood mononuclear cells (PBMCs) of subjects diagnosed with RA, PsA and SpA.

NCT ID: NCT03411057 Terminated - Clinical trials for Rheumatoid Arthritis

Mindfulness Based Stress Reduction in Rheumatic Diseases

MBSR
Start date: January 18, 2018
Phase:
Study type: Observational

This study will assess the mental health and clinical benefits of Mindfulness Based Stress Reduction (MBSR) in patients with rheumatic disease who have anxiety or depression. MBSR, an interactive form of meditation that includes gentle yoga, will be taught by a certified instructor over an eight-week period. Mental health surveys will be conducted within one month of the study start and end as well as mid-course. Clinical assessments will be conducted within one-month of the study start and end.